Author: Nichols Martin|| Date Published: July 31, 2020
Pharmaceutical company GlaxoSmithKline has been awarded a $342M contract by the U.S. Army to obtain COVID-19 vaccines in mass quantities from multiple vendors.
The service branch obligated the full contract amount at the time of award to support coronavirus response efforts at military sites within and outside the continental U.S., the Department of Defense said Thursday.
Army Contracting Command received one bid for the procurement.
Contract work will take place at Research Triangle Park in North Carolina through Feb. 28, 2021.
Kris Levin-Snow, area vice president within AT&T‘s national security group, will now oversee the company’s defense industrial base portfolio in addition…
Rocket Lab has signed a definitive agreement to acquire California-based Motiv Space Systems, adding space robotics and precision spacecraft mechanism…
Sonny Bhagowalia, assistant commissioner for information and technology and chief information officer at U.S. Customs and Border Protection, has received…
NextPoint Group expands intelligence-focused capabilities with UScontracting acquisition by adding expertise in cybersecurity, signals intelligence and data analysis for national…
